ALS

Genomics
#ALS #Genomics #Longitude Prize #OutSee

OutSee receives Discovery Award from Longitude Prize on ALS 

OutSee has received a Discovery Award from the Longitude Prize on ALS, the genomics and drug discovery company has announced.  The award will grant OutSee access to genomic data from 9,000 amyotrophic lateral sclerosis (ALS) patients, in addition to £100,000 ($134,000) in funding, supporting a research project… Read More

#News

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

DDW Highlights: 12 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the FDA advanced an initiative to implement real-time clinical trials. Elsewhere, UCB made… Read More

#Podcasts

Spinal motor neurone
#ALS #MND #University of Sheffield

University of Sheffield wins global prize for ALS project 

The University of Sheffield has been named as one of the winners of the Longitude Prize on ALS for a project using AI to combat motor neurone disease (MND).  The global prize recognised the Sheffield-led ‘Decode ALS’ consortium as one of the world’s most promising multidisciplinary teams… Read More

#News

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

This week in Drug Discovery (4 – 8 May) 

News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW.  This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture.  The top stories:    FDA moves… Read More

#News

Patient holding pill in hand
#ALS #Fast Track designation #FDA #Spinogenix

FDA grants Fast Track Designation to ALS pill 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for amyotrophic lateral sclerosis (ALS).  Tazbentetol, developed by biopharmaceutical company Spinogenix, is a once-a-day pill with potential to restore synapses, the key connections between neurons that allow people to think, plan, remember… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

#ALS #Axol Bioscience #LifeArc #MND

Global initiative to tackle gaps in ALS/MND drug discovery 

A global initiative has launched to close the gap in ALS/MND drug discovery.  The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience announced the launch of ‘Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modelling’ (PRISM ALS), a collaborative effort to expand access to high-quality, patient-derived stem… Read More

#News

#ALS #Fast Track designation #FDA

FDA grants Fast Track Designation to ALS treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a first-in-class vectorised antibody for the treatment of amyotrophic lateral sclerosis (ALS).  VTx-002, developed by biotechnology company VectorY Therapeutics, targets TDP-43 pathology, which drives up to 97% of ALS cases.  Fast Track is a process designed… Read More

#News #Regulatory

ALS concept
#ALS #Axoltis Pharma #Financing

Axoltis Pharma raises €18 million to advance ALS drug 

Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.  The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.  The financing round… Read More

#Business & Investment #News

#ALS #Antibody drug conjugate (ADC) #Breast cancer #DDW Highlights podcast #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Oncology

DDW Highlights: 2 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, gene therapies provided solutions for complex conditions, most notably in Hunter syndrome… Read More

#Podcasts

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

DDW Highlights: 18 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, groundbreaking research showed the Covid-19 mRNA vaccine could boost cancer response. Elsewhere,… Read More

#Podcasts

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

This week in Drug Discovery (10 – 14 November) 

News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW.  This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective… Read More

#News

#ALS #Arbor Biotechnologies #CNS #Financing #Gene therapy

Gene editing company announces $73.9m Series C financing

Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS).   The proceeds will support clinical development of the company’s lead therapeutic candidate,… Read More

#Business & Investment #News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 17 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week, DDW has opened registrations for its webinar ‘The latest… Read More

#News